# reload+after+2024-01-22 20:31:52.907951
address1§Novo Alle 1
city§Bagsvaerd
zip§2880
country§Denmark
phone§45 44 44 88 88
website§https://www.novonordisk.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
fullTimeEmployees§61412
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Lars Fruergaard Jorgensen', 'age': 57, 'title': 'President, CEO & Member of Management Board', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 4740897, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Karsten Munk Knudsen', 'age': 52, 'title': 'Executive VP, CFO & Member of the Management Board', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1878746, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Henrik Ehlers Wulff', 'age': 53, 'title': 'Executive VP of Product Supply, Quality & IT and Member of the Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1893423, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Camilla  Sylvest', 'age': 51, 'title': 'Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1849390, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Martin Holst Lange', 'age': 53, 'title': 'Executive VP of Development & Member of the Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1790679, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marcus  Schindler Ph.D.', 'age': 57, 'title': 'EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1790679, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Maziar Mike Doustdar', 'age': 53, 'title': 'Executive VP of International Operations & Member of the Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas J. Langa', 'age': 57, 'title': 'Executive VP of North America Operations & Member of Management Board', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ludovic  Helfgott', 'age': 49, 'title': 'Executive VP, Head of Rare Disease & Member of Management Board', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tania  Sabroe', 'title': 'Executive VP of Global People & Organisation and Member of Management Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§3
compensationRisk§1
shareHolderRightsRisk§9
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§1.03
dividendYield§0.0097
exDividendDate§1692316800
payoutRatio§0.42139998
fiveYearAvgDividendYield§1.71
beta§0.17
priceToSalesTrailing12Months§2.219053
currency§USD
dateShortInterest§1702598400
forwardEps§3.21
pegRatio§98.82
exchange§NYQ
quoteType§EQUITY
shortName§Novo Nordisk A/S
longName§Novo Nordisk A/S
firstTradeDateEpochUtc§357485400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ec4e324f-1461-36f1-bb32-2ca54d8984b3
gmtOffSetMilliseconds§-18000000
targetHighPrice§125.47
targetLowPrice§17.61
targetMeanPrice§84.63
targetMedianPrice§97.73
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§0.635
earningsGrowth§0.577
grossMargins§0.84142
ebitdaMargins§0.46672
trailingPegRatio§4.2321
